Last reviewed · How we verify
Maraviroc, Darunavir/r
This combination uses maraviroc to block HIV entry via the CCR5 co-receptor and darunavir/ritonavir to inhibit HIV protease, together suppressing viral replication through dual mechanisms.
This combination uses maraviroc to block HIV entry via CCR5 co-receptors and darunavir/ritonavir to inhibit HIV protease, together suppressing viral replication through dual mechanisms. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus.
At a glance
| Generic name | Maraviroc, Darunavir/r |
|---|---|
| Sponsor | Catholic University of the Sacred Heart |
| Drug class | Antiretroviral combination (CCR5 antagonist + protease inhibitor) |
| Target | CCR5 co-receptor (maraviroc); HIV protease (darunavir) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Maraviroc is a CCR5 antagonist that prevents HIV from binding to and entering CD4+ T cells by blocking the CCR5 chemokine receptor on the cell surface. Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins necessary for infectious particle maturation, while ritonavir acts as a pharmacokinetic booster. Together, they provide complementary antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-experienced patients with CCR5-tropic virus
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Elevated liver enzymes
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen (PHASE2)
- CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (PHASE4)
- Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (PHASE3)
- The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study (PHASE1)
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir (PHASE3)
- Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maraviroc, Darunavir/r CI brief — competitive landscape report
- Maraviroc, Darunavir/r updates RSS · CI watch RSS
- Catholic University of the Sacred Heart portfolio CI